There is a particular irony in the fact that Philip Morris International, the company whose Marlboro brand became synonymous with the global cigarette industry, is now generating more than four out of every ten dollars of revenue from products that do not involve smoking at all.

The company reported fourth-quarter results Friday morning that underscored the acceleration of its smoke-free transformation. Analysts expected earnings per share of $1.67, representing a 7.7% increase from the prior year, on revenue of approximately $10.4 billion. The report caps a fiscal year in which smoke-free products — primarily IQOS heated tobacco devices and ZYN nicotine pouches — crossed the 40% revenue threshold for the first time in the company's history.

The Smoke-Free Pivot, by the Numbers

Philip Morris's transformation from a traditional cigarette company into a diversified nicotine platform has been years in the making, but the pace of change accelerated dramatically in 2025 and into 2026. Smoke-free products accounted for 41% of the company's net revenues during the first nine months of 2025, up from roughly 35% in the same period of 2024 and just 14% as recently as 2019.

The growth is being driven by two distinct product categories, each targeting a different consumer need. IQOS, the company's heated tobacco system, heats processed tobacco sticks to approximately 350 degrees Celsius without burning them, producing an aerosol rather than smoke. The device has found its largest markets in Japan, where it commands more than 25% of the total nicotine market, and across Europe, where adoption has accelerated in countries including Italy, Germany, and Greece.

ZYN, the nicotine pouch brand that Philip Morris acquired through its $16 billion purchase of Swedish Match in 2022, has emerged as the company's fastest-growing product and one of the most successful consumer goods launches of the decade. The pouches, which deliver nicotine without tobacco, smoke, or vapor, have become a cultural phenomenon in the United States, particularly among younger adults seeking alternatives to both cigarettes and vaping.

ZYN's American Conquest

The ZYN story deserves particular attention because it illustrates how quickly consumer preferences can shift when an alternative product hits the right combination of convenience, social acceptability, and perceived harm reduction.

U.S. shipments of ZYN pouches have grown at a compound annual rate exceeding 50% since 2022. The brand now accounts for roughly 75% of the U.S. nicotine pouch market and has expanded into more than 180,000 retail locations, from gas stations and convenience stores to golf courses and concert venues. The product's discreet format — a small pouch tucked between the lip and gum — has made it acceptable in settings where smoking or vaping would be prohibited or socially frowned upon.

Demand has consistently outstripped supply, forcing Philip Morris to invest more than $800 million in new ZYN manufacturing capacity in the United States, including a major facility in Owensboro, Kentucky. Even with expanded production, certain flavors and nicotine strengths remain intermittently out of stock at retailers, a supply constraint that functions as a form of involuntary demand rationing.

The Cigarette Decline Continues

The growth of smoke-free products comes against a backdrop of ongoing decline in the traditional cigarette business. Global cigarette volumes have been falling at roughly 2% to 3% annually for over a decade, driven by public health campaigns, regulatory restrictions, tax increases, and the availability of alternatives like vaping and nicotine pouches.

For Philip Morris, the cigarette decline is manageable precisely because the margins on smoke-free products are improving rapidly. IQOS heated tobacco sticks carry margins comparable to premium cigarettes, while ZYN pouches, which require no tobacco leaf, have a cost structure that is inherently more favorable. As the revenue mix continues shifting toward smoke-free products, the company's overall profitability has the potential to expand even as cigarette volumes shrink.

This dynamic is what has made Philip Morris stock one of the best performers in the consumer staples sector. Shares have gained approximately 45% over the past twelve months, significantly outperforming both the S&P 500 and the company's tobacco industry peers.

Regulatory Risks and Opportunities

The regulatory landscape for smoke-free products remains the most significant source of uncertainty for Philip Morris's growth trajectory. The FDA's approach to nicotine pouches, heated tobacco, and vaping products continues to evolve, with the agency simultaneously cracking down on unauthorized flavored vaping products while considering modified risk designations for products like IQOS that may pose lower health risks than combustible cigarettes.

Philip Morris has positioned its regulatory strategy around the concept of "harm reduction," arguing that smokers who switch to non-combustible nicotine products significantly reduce their exposure to the toxicants produced by burning tobacco. The scientific evidence supporting this claim is substantial, though public health experts remain divided on whether promoting any nicotine product — even one with a lower risk profile — is appropriate from a population health perspective.

Internationally, the regulatory environment varies widely. Japan, which has embraced heated tobacco as a harm reduction tool, represents the most favorable regulatory framework. The European Union has taken a more cautious approach, imposing advertising restrictions and flavor limitations. Several developing markets in Africa and Southeast Asia remain largely unregulated, representing both growth opportunities and potential reputational risks.

Investment Implications

Philip Morris International presents investors with an unusual proposition: a legacy tobacco company that is actively disrupting its own core business. The company's ability to grow total revenue despite declining cigarette volumes is a testament to the strength of the smoke-free product portfolio, and the runway for continued growth remains substantial given that smoke-free products still represent a minority of global nicotine consumption.

The stock's valuation reflects this growth story. Philip Morris trades at a significant premium to traditional tobacco peers like British American Tobacco and Altria, a premium that is justified by faster revenue growth, improving margins, and a product portfolio that is better aligned with long-term consumer and regulatory trends.

For income investors, the company offers a dividend yield that, while lower than historical levels due to share price appreciation, remains competitive within the consumer staples sector. For growth investors, the ZYN and IQOS franchises provide a level of organic revenue growth that is rare among companies of Philip Morris's size and maturity.

The question facing investors is whether the current valuation adequately prices the growth ahead, or whether the stock's strong run has already captured the bulk of the smoke-free opportunity. Friday's earnings report will provide the latest data point in that ongoing calculation.